Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Market Cap: US$26.6b

Horizon Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Tim Walbert

Chief executive officer

US$20.1m

Total compensation

CEO salary percentage6.4%
CEO tenure15.3yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

CEO Compensation Analysis

How has Tim Walbert's remuneration changed compared to Horizon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

US$438m

Mar 31 2023n/an/a

US$372m

Dec 31 2022US$20mUS$1m

US$521m

Sep 30 2022n/an/a

US$574m

Jun 30 2022n/an/a

US$765m

Mar 31 2022n/an/a

US$862m

Dec 31 2021US$21mUS$1m

US$534m

Sep 30 2021n/an/a

US$552m

Jun 30 2021n/an/a

US$518m

Mar 31 2021n/an/a

US$280m

Dec 31 2020US$22mUS$1m

US$390m

Sep 30 2020n/an/a

US$792m

Jun 30 2020n/an/a

US$517m

Mar 31 2020n/an/a

US$592m

Dec 31 2019US$14mUS$1m

US$573m

Sep 30 2019n/an/a

US$82m

Jun 30 2019n/an/a

US$97m

Mar 31 2019n/an/a

US$77m

Dec 31 2018US$17mUS$1m

-US$38m

Sep 30 2018n/an/a

-US$178m

Jun 30 2018n/an/a

-US$275m

Mar 31 2018n/an/a

-US$460m

Dec 31 2017US$2mUS$1m

-US$350m

Sep 30 2017n/an/a

-US$495m

Jun 30 2017n/an/a

-US$437m

Mar 31 2017n/an/a

-US$212m

Dec 31 2016US$2mUS$950k

-US$166m

Compensation vs Market: Tim's total compensation ($USD20.10M) is above average for companies of similar size in the US market ($USD12.14M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


CEO

Tim Walbert (56 yo)

15.3yrs

Tenure

US$20,103,869

Compensation

Mr. Timothy P. Walbert, also known as Tim, serves as an Independent Director at Mirum Pharmaceuticals, Inc. from April 05, 2023. He is an Independent Director of Century Therapeutics, Inc. since September...


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman15.3yrsUS$20.10mno data
Aaron Cox
Executive VP of Finance & CFO1.4yrsUS$7.17m0%
$ 0
Sean Clayton
Executive VP & General Counsel1.7yrsUS$10.87m0%
$ 0
Andy Pasternak
Executive VP & Chief Strategy Officer3.9yrsUS$6.75m0%
$ 0
Elizabeth Thompson
Executive Vice President of Research & Development2.6yrsUS$8.48m0%
$ 0
Patrick McIlvenny
Senior VP & Chief Accounting Officerless than a yearno data0%
$ 0
Tina Ventura
Senior VP & Chief Investor Relations Officerno datano datano data
Geoffrey Curtis
Executive VP of Corporate Affairs & Chief Communications Officer7.8yrsno datano data
Keli Walbert
Executive VP & Chief Marketing Officerless than a yearno datano data
Jane Gonnerman
Senior VP of Corporate Development & Chief of Staff2yrsno datano data
Irina Konstantinovsky
Executive VP6.1yrsUS$2.31mno data
Jeffrey Sherman
Executive VP & Chief Medical Officerno dataUS$5.86m0%
$ 0

2.3yrs

Average Tenure

48yo

Average Age

Experienced Management: HZNP's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Walbert
Chairman15.3yrsUS$20.10mno data
Michael Grey
Lead Independent Director12.1yrsUS$551.24k0%
$ 0
William Daniel
Independent Director9.1yrsUS$522.49k0%
$ 0
Jeff Himawan
Independent Director16.3yrsUS$504.36k0%
$ 0
Gino Santini
Independent Director11.6yrsUS$494.99k0%
$ 0
H. Watkins
Independent Director9.5yrsUS$506.24k0%
$ 0
James Shannon
Independent Director6.2yrsUS$510.61k0%
$ 0
Susan Mahony
Independent Director4.2yrsUS$514.36k0%
$ 0
Pascale Witz
Independent Director6.2yrsUS$496.24k0%
$ 0

9.5yrs

Average Tenure

66yo

Average Age

Experienced Board: HZNP's board of directors are considered experienced (9.5 years average tenure).